MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

Excerpt from the Press Release:

LA JOLLA, Calif., June 05, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the prevention of metastasis in various cancers including pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, and ovarian cancer.

Once issued, this patent is expected to expire no earlier than July 2042. The allowed claims cover the use of MN-166 (ibudilast) in combination with one or more additional therapies including chemotherapy, immunotherapy, radiotherapy, photodynamic therapy, epigenetic therapy, and liver-directed therapy and others. The allowed claims specifically cover the use of MN-166 (ibudilast) for preventing, ameliorating, or minimizing metastasis of various cancers including pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, or ovarian cancer. The allowed claims cover oral administration, a wide range of doses, a range of different dosing frequencies, and a range of different treatment periods.

Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, “Cancer metastasis is often the major driver of cancer-related deaths rather than the primary cancer. Recently we were granted a patent ^*1 to cover preventing metastasis of uveal melanoma.

Click the button below to read the entire Press Release:

Continue Reading The Press Release